Savara (NASDAQ:SVRA) Stock Price Down 5.3% – Should You Sell?

Savara Inc (NASDAQ:SVRA)’s stock price fell 5.3% during mid-day trading on Thursday . The stock traded as low as $2.90 and last traded at $2.93. 392,669 shares changed hands during trading, a decline of 58% from the average session volume of 929,169 shares. The stock had previously closed at $3.09.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SVRA. Wells Fargo & Company began coverage on Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price on the stock. Evercore ISI restated an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Thursday, December 19th. Finally, HC Wainwright decreased their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Savara currently has an average rating of “Moderate Buy” and a consensus target price of $9.86.

Savara Trading Up 0.7 %

The firm has a market cap of $502.85 million, a P/E ratio of -6.81 and a beta of 0.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a 50 day moving average of $3.23 and a 200 day moving average of $3.86.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, equities research analysts predict that Savara Inc will post -0.45 EPS for the current year.

Insider Buying and Selling at Savara

In other Savara news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Joseph S. Mccracken acquired 20,000 shares of the stock in a transaction on Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 5.13% of the company’s stock.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP increased its stake in shares of Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after purchasing an additional 1,600,000 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after acquiring an additional 4,157,385 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Savara by 10.8% during the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock valued at $11,564,000 after acquiring an additional 264,825 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Savara by 238.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after acquiring an additional 642,259 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its position in shares of Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.